The bottom line
1The headline thesis
36.8%
RCH share of its core inpatient market — 63% leaks out (HCAI CY2024)
-$8.6M
FY2024 operating loss; 6 of 14 years negative (IRS 990)
-31%
inpatient discharges since 2018 (13,946 → 9,604); births -38%
~22,000
capturable commercial lives vs. 1,405 on RCH's plan today
The argument in one paragraph
RCH owns two genuinely defensible assets — a dominant ED front door (~57–59% home-ZIP share on 61,472 visits) and a VRIO ortho/spine franchise — but it leaks value at exactly the two layers a prevention-first system must own: pre-service primary care and after-service population health. With discharges down 31%, an operating loss, and 63% of core-market inpatients leaking out, standing still is the value-destructive option, not the safe one. The right move is forward vertical integration by cooperation-before-purchase — aggregate the corridor's ~320 independent physicians into an RCH-led clinically integrated network (CIN), convert ED loyalty into retained admissions, and grow ambulatory/ASC capacity where demand is actually migrating — executed at the lowest compliant regulatory rung.
The binding constraint isn't the market — it's execution
A money-losing, sub-scale hospital with an incoming CEO (Jan 2026) and no population-health muscle cannot stand up a CIN, MSO, ASC, friendly-PC, and at-risk contracting all at once. So the recommendation is disciplined: green-light Horizon 1 only (CIN + transfer-prevention + direct-to-employer + a hard quality fix). The §1206(l) foundation, Knox-Keene risk-bearing, and an owned health plan are conditional options to be earned — not a committed roadmap.
Intellectual honesty
2What our own review changed
A draft was put through three adversarial reviews — market realism, regulatory feasibility, financial realism — before anything was recommended. The strategy's spine survived; three optimistic claims did not. This is what separates analysis from a brochure.
Correction 1 — the recapturable leak is smaller
The winnable leak is ~2,500–3,100 discharges, not ~5,100. Re-running the source data, ~70% of the leak is structurally locked: Kaiser closed-network (~1,661) plus LLU/Arrowhead tertiary/trauma/peds (~3,000+) a 211-bed no-trauma hospital can't serve. Realistic target: lift core share 36.8% → 40–42%, reported in contribution margin (~+$2–5.5M), not the ~$14M gross-revenue figure.
Correction 2 — the "ED conversion gap" is a mirage
RCH already admits ~5,625 ED patients — ~59% of all discharges already flow through its ED. The 10.1% admit-to-visit ratio is a normal treat-and-release pattern, not an 18-point recoverable gap. The real lever is transfer-prevention + downstream referral capture — and those dollars must not be stacked on share-recapture dollars.
Correction 3 — the balance sheet can't fund it
"51 days of cash" is net assets ÷ daily opex — not cash. True unrestricted days-cash is materially lower once PP&E and restricted funds are excluded. External capital — a risk-enablement JV / managed-services partner and/or a philanthropy campaign — is a precondition of starting, not a fallback.
What held up
Forward vertical integration via cooperation-before-purchase (CIN anchored by CAMG + the now-independent RYMG); focused differentiation (concede trauma/peds/quaternary to Loma Linda; win on local, integrated, lower-total-cost community care); a Phase 0 quality fix as a stop/go gate; and the SB351 hospital carve-out as a real recruiting advantage over payer-owned Optum.
Demand & leakage
3Sizing the recapture prize — and what's actually winnable
In RCH's core draw area (Redlands · Yucaipa · Mentone · Calimesa, 15,513 inpatient discharges) RCH keeps just 36.8%. Lifting share moves the operating line — but most of the leak is structurally locked.
The recapture scenarios
| Target core share | Disch. | Incr. | Net IP rev* |
|---|---|---|---|
| 36.8% (today) | 5,712 | — | — |
| 42% | 6,515 | +803 | +$14.0M |
| 46% | 7,136 | +1,424 | +$24.8M |
| 50% | 7,756 | +2,044 | +$35.7M |
*@ ~$17,448 net IP rev/discharge (HCAI). Gross planning estimate; the review caps the board target at 40–42% and reports it in contribution margin (~+$2–5.5M).
But only ~half the leak is winnable
| Leakage bucket | Disch. | Recapturable? |
|---|---|---|
| Kaiser closed-network | ~1,661 | No |
| Tertiary / peds / trauma → LLU & Arrowhead | ~3,032 | No |
| Community-acuity (residual) | ~5,108 | Yes |
The structurally recapturable pool implies a realistic share ceiling near 70%, not 100% — worth ~$89M at full capture, but no standalone community hospital wins all of it.
The asymmetry that defines the strategy
RCH wins the front door it has (≈57–59% ED share in home ZIPs) but loses the patient it should keep (only 36.8% of inpatients). Demand is also shifting under it: ED visits +44% since 2018, outpatient surgery now exceeds inpatient, while admissions and births fall. The play is to convert ED gravity and ambulatory growth into retained, longitudinal relationships — not to defend a shrinking med-surg core. See the full market model →
The market-entry refinement you asked for
4Resident lives vs. daytime-worker lives
A covered-lives count built on employer location (who works at a Redlands employer) is not the same market as residence (who lives in the service area) — and network efficiency is governed by where people live. The Census commuting data shows the two populations are largely different people in different places.
14.9%
of Redlands' 39,161 jobs are held by Redlands residents (live+work)
85.1%
of those jobs are filled by in-commuters who live elsewhere
1.26
jobs-housing ratio → a net in-commute employment center
~24.9 min
mean resident commute — but 81% of residents work out-of-city
Why the employer-based TAM is diluted
Of the ~33,000 people who work in Redlands but live elsewhere, roughly two-thirds live outside the efficient (~15-minute) service area (top origins: San Bernardino, Yucaipa, Highland, Riverside, Moreno Valley, Fontana, even Los Angeles). A worker who commutes in from Moreno Valley will not pick a Redlands PCP or route their family's care through RCH — they'll use a Redlands network only for what happens at the worksite during the workday.
Three populations, two lines of business
| Segment | Who | RCH network efficient? | The right play |
|---|---|---|---|
| Resident lives | Live in the service area (incl. the bedroom-community ring) | Yes | Own the relationship: CIN, primary care, value-based/ACO, a provider-sponsored plan |
| Daytime-worker lives | Work in Redlands, live elsewhere (~33,000) | No | Serve episodically, payer-agnostic: occ-health, near-site employer clinics, urgent care, imaging, ED, ASC, ortho/spine COE, direct-to-employer bundles |
| Out-commuters | Live in Redlands, work elsewhere (~24,900, mostly <15 min away) | Yes | Capture as residents: stay broadly contracted (open PPO); prime targets for the CIN & a resident plan — invisible to an employer count |
How to account for it — the residence haircut
Size the narrow-network / provider-sponsored-plan TAM on ~0.40–0.45× employer-based lives, not 1.0×: only the ~15% who live+work plus the ~32% near-resident slice of in-commuters are efficient to anchor. Treat the remaining ~55–60% as out-of-area worker lives that won't anchor longitudinally. Then add resident out-commuters back in from Census household population — they're efficient lives the employer roster misses.
Services other payers would route to
The daytime-worker population is a separate, B2B revenue line sized on the full ~39,000-job daytime base (plus ~22,000 in Loma Linda, ~119,000 in San Bernardino): occupational-health PMPM/PEPM, near-site clinics for ESRI / Amazon / the District, and Centers of Excellence (ortho/spine, cardiac) that any payer routes to on price/quality — leakage-proof revenue independent of owning the member's insurance.
The regional pattern
No city in the study area is self-contained. Loma Linda (jobs-housing 2.15) and San Bernardino (1.45) are in-commute employment centers; Yucaipa, Highland (0.26), Mentone, Grand Terrace, Calimesa, Beaumont, Banning are out-commute bedroom communities (0.26–0.50) — dense reservoirs of resident lives whose care defaults home. Those JH<1 dormitories are an asset, not a liability. (Sources: LEHD LODES8 2022; ACS 2024 5-yr. See commuter_resident_analysis.csv/.md.)
Net effect on the plan
The single most important modeling error to avoid is letting the impressive 39,000-job workplace number set the size of a plan whose members must, by the data, mostly live somewhere else. Use residence as the unit of geography for anything longitudinal; use workplace geography only for the worksite/COE line.
Industry structure
5Porter's Five Forces — where RCH is boxed in
| Force | Rating | Why |
|---|---|---|
| Supplier power (physicians) | High | Binding constraint #1. Optum/Beaver — the largest medical group — is owned by UnitedHealth (a payer) and gatekeeps referrals; CPOM bars RCH from out-employing it |
| Rivalry | High | Binding constraint #2. LLU (academic, Level I trauma, peds) takes ~28% of the core leak; Kaiser closed-network ~11%; Dignity & Arrowhead in the broader ring |
| Buyer power | Med-High | Commercial payers, self-funded employers, Medi-Cal MCOs (IEHP/Molina), price transparency |
| Substitutes | Med-High | Telehealth, urgent care, ASCs vs. HOPD, home-based care, direct primary care |
| New entrants | Medium | Kaiser expansion, ASC proliferation, retail/CVS/Amazon/Optum clinics, FQHC growth (Neighborhood Healthcare-Beaumont) |
The two binding forces share one root cause — and one cure
Supplier power and rivalry both trace to a sub-scale hospital whose physician feeder is being absorbed by a payer it can't legally out-employ. The single move that attacks both is the CIN — it converts the most-feared supplier into an owned (aligned) asset. See the competitor map →
Synthesis
6SWOT → TOWS
TOWS forces internal strengths/weaknesses to be matched against external opportunities/threats — producing four action postures, not a static list.
| Opportunities — ~5,100 recapturable discharges; ~320 independent PCPs; ~22,000 capturable lives; Pass whitespace; CalAIM/VBC tailwinds; ambulatory migration | Threats — Optum gatekeeper + CPOM; LLU encroachment; -6%/yr inpatient decay; Kaiser lock; AB1415/OHCA clock; FQHC/retail entrants; 2030 seismic capex | |
|---|---|---|
| Strengths — ED front door; ortho/spine; 120-yr brand + #3 employer; 56.6% occupancy headroom; SB351 carve-out | SO — Offensive. Convert ED dominance into retained admissions; build the CIN nucleus around Yucaipa by signing CAMG + RYMG first; weaponize SB351 as a "stay independent, stay local" recruiting asset; fund ASC/RPM from outpatient strength. | ST — Defensive. Aggregate the ~320 independents now to neutralize Optum before the pool is absorbed; compete on focused differentiation (elective ortho/spine, access), conceding trauma/peds to LLU via affiliation; own the ASC channel. |
| Weaknesses — operating loss + thin cushion; inpatient/OB decline; CMS 2-star vs. 4-star marketed + stroke mortality; no owned PCP base; sub-scale | WO — Improvement. Fix the quality-credibility gap as Phase 0 before any negotiation; sequence the build cash-generative (harvest ortho/ambulatory first, defer Knox-Keene); open with zero-license direct-to-employer contracts. | WT — Survival. Don't chase the full 63% leak — anchor to the ~52% recapturable pool at a 40–46% band; secure external capital before the window closes; adopt a "lowest-compliant-rung" deal doctrine under SB351/AB1415. |
The SO quadrant is where Redlands Health wins and should command the first capital; the WO quadrant (quality fix) is the gating prerequisite; the ST quadrant (the CIN) resolves the strategy's central tension.
Direction
7Three growth horizons
Recommended directional strategy (Ginter): expansion via forward vertical integration + related diversification + market development, with a disciplined contraction call on sub-scale acute lines. Entry vehicle: cooperation before purchase. Competitive posture: focused differentiation.
| Horizon | Ginter strategy / vehicle | The core move | Quantified prize |
|---|---|---|---|
| H1 · Stop the Leak 0–2 yrs · committed | Penetration + light forward integration · Cooperation (CIN + MSO) | Form the CIN (CAMG, RYMG, Arrowhead Ortho, IPAs); convert the ED moat into admissions; rung-1 direct-to-employer (ESRI, RUSD, RCH's own plan) | 36.8% → 42% core share ≈ +$2–5.5M contribution (≈ +$14M gross); transfer-prevention |
| H2 · Build the System 2–5 yrs · conditional | Full forward integration + diversification + market development · Cooperation → JV | Friendly-PC + MSO primary-care base; shared-savings; San Gorgonio Pass expansion; hospital-at-home + RPM for the high-cost tier | 46–50% share band ≈ +$25–36M; high-cost ~5–6% drive ~50% of spend |
| H3 · Own the Model 5–10 yrs · option only | Related diversification (provider-sponsored plan) · Knox-Keene + §1206(l) | Restricted → full Knox-Keene plan; §1206(l) foundation; regional consolidation — only after the CIN demonstrably manages cost | 1,405 → ~22,000 capturable lives (15×); CIN ceiling ~700,000 |
Discipline
Only H1 is a committed program. H2 and H3 are explicitly classified as conditional options to be re-approved on evidence — not a pre-committed 10-year roadmap. Each larger move is earned, not assumed.
The money
8Financial & value-creation case
An illustrative value bridge — annual contribution to operating income. Planning estimates, not actuarial. The cheapest rung (the no-license CIN) carries the most value, which is what makes the program financeable.
| Value-bridge step | Δ Operating |
|---|---|
| FY2024 operating result (start) | -$8.6M |
| + Inpatient recapture to 46% core share | +$8.7M |
| + Ambulatory / ASC line (2,000 cases) | +$3.1M |
| + CIN shared savings (~115k lives, mid) | +$15.0M |
| + Owned plan, Year 1 (7k lives) | +$2.8M |
| − CIN / care-management overhead | -$8 to 12M |
| Steady-state operating swing | +$9 to +$13M |
Conservative on inpatient (46%, not 50%); biggest contribution rests on the no-license CIN rung. See the editable Pro Forma →
Investment & payback
- $60–110M phased: CIN/MSO + care-mgmt IT $8–15M (Yr 0–1); aligned PC / §1206(l) $20–40M (Yr 1–4); ASC capex $15–25M (Yr 1–3); Knox-Keene reserves $15–30M (deferred to rung 4); working capital / J-curve $10–20M.
- Self-funding by sequence: the no-license CIN rung earns ~$10.6–19.8M/yr at ~2–3 yr payback on its slice; ED-to-IP recapture lands against an existing fixed-cost base at 56.6% occupancy. Blended payback ~4–6 yrs.
Honest counterweight
The thesis depends on three things RCH lacks: external capital (thin cushion, 6/14 negative years), quality credibility (the 2-star/4-star gap, fixed as Phase 0), and sequencing discipline (CPOM, the AB1415/OHCA clock, the Knox-Keene ladder). Get these right and the math holds; get them wrong and -6%/yr decay erases the opportunity first.
The roadmap
9Recommendations & first 90 days
Top recommendations
- Green-light Horizon 1 only as a committed program; classify H2/H3 as conditional options.
- Phase 0 quality fix = hard stop/go gate: re-enter Leapfrog, remediate stroke mortality, reconcile the 2-star-live vs. 4-star-marketed claim. No term sheet is signed until underway.
- External capital is a precondition: a risk-enablement JV / managed-services partner (turnkey CIN/MSO platform) + a philanthropic campaign on the $58M community-benefit story.
- Re-underwrite recapture: one denominator, cap at 40–42%, report contribution margin, don't stack the ED lever.
- Fund organizational readiness as line items: named CEO sponsor + guiding coalition (Kotter), VP Population Health, CIN executive director; cap concurrent initiatives per 18-month window.
- Treat CAMG & RYMG as binary risks; model first-wave lives without RYMG. Win physicians on deliverable economics, not SB351 alone.
First 90 days
- Board + incoming CEO adopt the Horizon-1-only mandate; name the sponsor and coalition.
- Launch Phase 0 quality remediation; correct the public star-rating claim within 30 days.
- Commission a true-liquidity re-underwrite (audited unrestricted days-cash, covenants, 2030 seismic).
- Open talks with 2–3 risk-enablement/MSO partners; frame the philanthropic campaign.
- Pull ED-to-IP case-mix/DRG data to separate community-acuity from tertiary before booking any recapture.
- Counsel-led exploratory talks with CAMG, RYMG, Arrowhead Ortho, the IPAs — with a no-RYMG fallback model.
- Stand up rung-1 direct-to-employer outreach (ESRI, RUSD); convert RCH's 1,405-life plan into the CIN proof-of-concept.
- Bring an explicit OB defend-or-harvest decision memo to the board.
Risk register
10The risks that can kill it
| Risk | Mitigation |
|---|---|
| Execution / change-capacity failure — the fatal risk; the most common way these transformations fail | Gate the program behind a funded readiness workstream + turnkey partner platform; cap concurrent initiatives; make Phase 0 a proof the org can execute |
| J-curve / liquidity trap — shared-savings cash arrives years 2–3, not day one | Re-underwrite on audited days-cash; external capital as precondition; model savings on a 3–5 yr J-curve |
| Recapture over-claim — ~70% of leak structurally locked; recaptured mix is Medi-Cal-skewed | Cap at 40–42% on one denominator; report contribution margin; validate with DRG data first |
| Anchor concentration — lives lean on RYMG/CAMG; Optum can out-bid or out-wait | Model lives without RYMG; treat each anchor as binary with a named owner; sign fast on the re-independence tailwind |
| Regulatory delay — AB1415/OHCA + AG review can bundle/slow deals | Assume one 6–12 month CMIR slip; start the 90-day clock early; stage deals individually |
What Redlands Health becomes
RCH the standalone hospital — running a loss on a shrinking inpatient core — becomes Redlands Health: the independent, prevention-first regional system that out-cared the giants it could never out-scale. A Yucaipa family keeps an independent primary-care doctor backed by an RCH-led network; surgery happens down the road at a Redlands ASC, not 40 minutes north; a parent in the ED is admitted and recovered at RCH, not transferred away; and the lives — once 1,405 on a tiny plan — number in the tens of thousands. Reachable, but only on the honest path: win quality credibility first, prove the model at the lowest compliant rung with partner capital, and earn each larger move.
← Market Opportunity · RCH Data · Competitor Map · Pro Forma
Method & sources. This page condenses an 18,700-word engagement (Strategic_Analysis_Consulting_Report.md) produced via a multi-agent, consulting-style workflow: six discovery workstreams (PESTEL, Five Forces, market/leakage, value-chain/financial, payer/lives, regulatory), a strategy table (SWOT/TOWS, growth horizons, financial case), an adversarial partner review (market, regulatory, financial realism), and a managing-partner synthesis. Data: CMS Care Compare/PDC; California HCAI (Annual Utilization Report; Patient Origin/Market Share Pivot Profile, CY2024); IRS Form 990 (ProPublica); DOL Form 5500/Schedule A; CMS NPPES; City of Redlands ACFR FY2024-25; U.S. Census LEHD LODES8 (2022) & ACS 2024 5-yr for the commuting analysis. Caveats: CMS 2-star (live) vs. 4-star (marketed); no service-line/DRG detail in the HCAI patient-origin file; modeled lives/take-up and the residence haircut are planning estimates; verify Form 990 against source PDFs; California-only leakage. Not medical, legal, actuarial, or investment advice.